The results (mean SD for 3 independent samples) are expressed as percentage of late apoptotic/necrotic cells. cells and that targeting MUC1-C inhibits the FLT3 signaling pathway. Our findings support the development of MUC1-C inhibitors alone and in combination with agents that target FLT3 for IgG2b/IgG2a Isotype control antibody (FITC/PE) the treatment of wild-type and mutant FLT3 AML. == Introduction == The FMS-like tyrosine kinase 3 (FLT3) receptor is a member of the class III subfamily that includes the FMS, KIT, and PDGF receptors. FLT3 is expressed by hematopoietic stem/progenitor cells and functions in the regulation of their proliferation and differentiation.1The FLT3 receptor is also expressed in more than 90% of acute myeloid leukemia (AML) blasts.2FLT3 is activated by FLT3 ligand, a transmembrane protein that is widely expressed by cells in the bone marrow, spleen, and epithelial tissues.1,3Activation of FLT3 by its ligand is associated with autophosphorylation of tyrosine residues in the FLT3 cytoplasmic domain and thereby the generation of docking sites for mitogenic downstream effectors. Specifically, the phosphoinositide 3-kinase (PI3K) p85 subunit interacts Procaine HCl with the autophosphorylated FLT3 cytoplasmic domain and, in turn, confers activation of AKT.4,5FLT3 also interacts with RAS and thereby activates the RASRAFmitogen-activated protein kinase (MEK)extracellular signal-regulated kinase (ERK) pathway.4,5Importantly, somatic mutations in the FLT3 gene have been identified in on the subject of 30% of patients with AML.1Among these mutations, the most common type is the internal tandem duplication (ITD).6The FLT3-ITD mutation results in loss of the FLT3 autoinhibitory function and constitutive activation of the kinase.1In this way, the FLT3-ITD receptor confers activation of the PI3KAKT and RASRAFMEKERK pathways.7Of importance clinically, patients with AML blasts harboring FLT3-ITD mutations have an increased risk of relapse and decreased survival.8Thus, FLT3-ITD has emerged as a stylish target for drug development. Accordingly, the FLT3 inhibitor, PKC412 (midostaurin),9has been used to treat individuals with FLT3 mutant AML with reactions that have been typically partial and transient.10,11Moreover, treatment of individuals with FLT3-ITD AML with the FLT3 inhibitor AC220 demonstrated a composite complete response rate of approximately 50%12,13and that relapses were mediated by reactivation of Procaine HCl FLT3 kinase Procaine HCl activity.14 Mucin 1 (MUC1) is a heterodimeric protein that is normally expressed in the apical borders of epithelial cells.15,16Intriguingly, MUC1 is aberrantly expressed in AML blasts17,18and in AML stem cells19; however, the functional part of MUC1 in AML is definitely unknown. Of importance to understanding its function, MUC1 consists of 2 subunits that form a stable complex in the cell surface.15,16The extracellular N terminal subunit (MUC1-N) contains a glycosylated tandem repeat structure that is characteristic of the mucin family.15,16The transmembrane C terminal subunit (MUC1-C) contains a 58-amino acid (aa) domain that extends outside the cell, a 28-aa transmembrane region, and a 72-aa cytoplasmic domain.15,16In epithelial cells, the MUC1-C subunit associates with receptor tyrosine Procaine HCl kinases (RTKs), such as epidermal growth factor receptor (EGFR) and ErbB2-4, in the cell membrane and contributes to their downstream signaling.15,16Phosphorylation of the MUC1-C cytoplasmic website on tyrosines by RTKs and SRC results in binding sites for PI3K and GRB2/SOS, linking MUC1-C to the AKT and RAS pathways, respectively.15,16MUC1-C has also been linked to activation of transmission transducer and activator of transcription 1/3 (STAT1/3) signaling.20,21In this capacity to interact with mitogenic pathways, expression of MUC1-C is sufficient to induce anchorage-independent growth and tumorigenicity.22,23The oncogenic function of the MUC1-C subunit is dependent on the formation of homodimers through a CQC motif in the MUC1-C cytoplasmic domain.15,24Based about these observations, cell-penetrating peptides have been designed that bind to the MUC1-C CQC motif and block MUC1-C homodimerization and function.25,26Significantly, treatment of AML cell lines and blasts with MUC1-C inhibitors is associated with growth inhibition and death induction.19,27These findings provided support for the dependence Procaine HCl of AML cells about MUC1-C for his or her survival. The present studies demonstrate that MUC1-C associates with FLT3 in AML cells. The results show that focusing on MUC1-C (1) disrupts MUC1-C/FLT3 complexes, (2) downregulates FLT3 activation, and (3) suppresses downstream AKT, ERK, and STAT5 signaling. Focusing on MUC1-C is also effective in inhibiting growth and inducing death of AML cells resistant to FLT3 inhibitors. == Methods == == Cell tradition and reagents == Human being MOLM-14, MOLM-13, MV4-11, HL-60, mouse BaF3/FLT3 (wild-type [WT]), BaF3/FLT3-ITD, and BaF3/FLT3-D835Y cell lines were managed in RPMI1640 medium comprising 10% heat-inactivated fetal bovine serum, 100 models/mL penicillin, 100.